User profiles for "author:Takashi Nishimura"
Takashi NISHIMURAGunma University Verified email at gunma-u.ac.jp Cited by 4694 |
The critical role of type‐1 innate and acquired immunity in tumor immunotherapy
The discovery of a large array of tumor antigens has demonstrated that host lymphocytes
can indeed recognize and destroy tumor cells as originally proposed in the cancer …
can indeed recognize and destroy tumor cells as originally proposed in the cancer …
The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and …
H Kitamura, K Iwakabe, T Yahata… - The Journal of …, 1999 - rupress.org
The natural killer T (NKT) cell ligand α-galactosylceramide (α-GalCer) exhibits profound
antitumor activities in vivo that resemble interleukin (IL)-12–mediated antitumor activities …
antitumor activities in vivo that resemble interleukin (IL)-12–mediated antitumor activities …
CRMP-2 binds to tubulin heterodimers to promote microtubule assembly
Y Fukata, TJ Itoh, T Kimura, C Ménager… - Nature cell …, 2002 - nature.com
Regulated increase in the formation of microtubule arrays is thought to be important for
axonal growth. Collapsin response mediator protein-2 (CRMP-2) is a mammalian …
axonal growth. Collapsin response mediator protein-2 (CRMP-2) is a mammalian …
Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo
T Nishimura, K Iwakabe, M Sekimoto, Y Ohmi… - The Journal of …, 1999 - rupress.org
The role of T helper type 1 (Th1) and Th2 cells in tumor immunity was investigated using Th
cells induced from ovalbumin (OVA)-specific T cell receptor transgenic mice. Although Th1 …
cells induced from ovalbumin (OVA)-specific T cell receptor transgenic mice. Although Th1 …
CRMP-2 induces axons in cultured hippocampal neurons
In cultured hippocampal neurons, one axon and several dendrites differentiate from a
common immature process 1. Here we found that CRMP-2/TOAD-64/Ulip2/DRP-2 (refs. 2–4) …
common immature process 1. Here we found that CRMP-2/TOAD-64/Ulip2/DRP-2 (refs. 2–4) …
JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias
A Nogami, T Kurita, H Abe, K Ando, T Ishikawa… - Circulation …, 2021 - jstage.jst.go.jp
Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …
coverage in Japan in 1974, and its use rapidly became widespread thereafter …
PAR-6–PAR-3 mediates Cdc42-induced Rac activation through the Rac GEFs STEF/Tiam1
A polarity complex of PAR-3, PAR-6 and atypical protein kinase C (aPKC) functions in
various cell-polarization events, including neuron specification,,,. The small GTPase Cdc42 …
various cell-polarization events, including neuron specification,,,. The small GTPase Cdc42 …
[HTML][HTML] Numb controls integrin endocytosis for directional cell migration with aPKC and PAR-3
T Nishimura, K Kaibuchi - Developmental cell, 2007 - cell.com
Migrating cells extend protrusions to establish new adhesion sites at their leading edges.
One of the driving forces for cell migration is the directional trafficking of cell-adhesion …
One of the driving forces for cell migration is the directional trafficking of cell-adhesion …
[HTML][HTML] Linking cell cycle to asymmetric division: Aurora-A phosphorylates the Par complex to regulate Numb localization
Drosophila neural precursor cells divide asymmetrically by segregating the Numb protein
into one of the two daughter cells. Numb is uniformly cortical in interphase but assumes a …
into one of the two daughter cells. Numb is uniformly cortical in interphase but assumes a …
The critical role of Th1-dominant immunity in tumor immunology
T Nishimura, M Nakui, M Sato, K Iwakabe… - Cancer chemotherapy …, 2000 - Springer
To investigate the precise role of antigen-specific Th1 and Th2 cells in tumor immunity, we
developed a novel adoptive tumor-immunotherapy model using OVA-specific Th1 and Th2 …
developed a novel adoptive tumor-immunotherapy model using OVA-specific Th1 and Th2 …